VYXEOS (Jazz Pharmaceuticals, Inc.)
Welcome to the PulseAid listing for the VYXEOS drug offered from Jazz Pharmaceuticals, Inc.. This Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [Chemical/Ingredient],Topoisomerase Inhibitors [MoA],Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Jazz Pharmaceuticals, Inc. |
| NON-PROPRIETARY NAME: | (daunorubicin and cytarabine) liposome |
| SUBSTANCE NAME: | CYTARABINE; DAUNORUBICIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [Chemical/Ingredient],Topoisomerase Inhibitors [MoA],Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-08-03 |
| END MARKETING DATE: | 0000-00-00 |
VYXEOS HUMAN PRESCRIPTION DRUG Details:
| Item Description | VYXEOS from Jazz Pharmaceuticals, Inc. |
| LABELER NAME: | Jazz Pharmaceuticals, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100; 44(mg/20mL; mg/20mL) |
| START MARKETING DATE: | 2017-08-03 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 68727-745_238f70d2-26f4-44c8-82fc-9aac10466f75 |
| PRODUCT NDC: | 68727-745 |
| APPLICATION NUMBER: | NDA209401 |
Other CYTARABINE; DAUNORUBICIN Pharmaceutical Manufacturers / Labelers:
